Skip to main content
. Author manuscript; available in PMC: 2021 Oct 5.
Published in final edited form as: J Am Coll Cardiol. 2021 Oct 5;78(14):1437–1449. doi: 10.1016/j.jacc.2021.07.056

TABLE 2.

Human Cohort 2 Participant Characteristics (n = 7)

Age, y (at start of study) 36 ± 6
Female 3 (43)
BMI, kg/m2 23 ± 3
Plasma profile at baseline (before PCSK9i therapy)
 PCSK9, ng/mL 214 ± 121
 Total cholesterol, mg/dL 184 ± 45
 LDL-C, mg/dL 104 ± 31
 HDL-C, mg/dL 65 ± 18
 Triglycerides, mg/dL 71 ± 19
PCSK9i single injection
 Alirocumab (75 mg) 3
 Evolocumab (140 mg) 4

Values are mean ± SD, n (%), or n.

Abbreviations as in Table 1.